Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
4
67%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Other(5)

Detailed Status

unknown5
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 24 (66.7%)

Trials by Status

not_yet_recruiting117%
unknown583%

Recent Activity

0 active trials
Showing 5 of 6
not_yet_recruitingphase_2

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

NCT07327411
unknownphase_2

Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy

NCT04508829
unknownphase_2

Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma

NCT03713372
unknownphase_1

A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC

NCT03491709
unknownphase_1

Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux

NCT03881787
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07327411Phase 2

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Not Yet Recruiting
NCT04508829Phase 2

Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy

Unknown
NCT03713372Phase 2

Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma

Unknown
NCT03491709Phase 1

A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC

Unknown
NCT03881787Phase 1

Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux

Unknown
NCT03744208Phase 2

SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6